FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200468462> ?p ?o ?g. }

• W4200468462 endingPage "1906" @default.
• W4200468462 startingPage "1906" @default.
• W4200468462 abstract "Ischemic stroke is a leading cause of death and disability throughout the world. Antithrombotic therapy, which includes both antiplatelet and anticoagulant agents, is a primary medication of choice for the secondary prevention of stroke. However, the choices vary with the need to incorporate evolving, newer information into the clinical scenario. There is also the need to factor in co-morbid medical conditions as well as the cost ramifications for a particular patient as well as compliance with the regimen. Pertinent Updates: In the acute setting, dual antiplatelet therapy from three weeks to up to three months has become recognized as a reasonable approach for patients with either minor stroke or transient ischemic attack or those with symptoms associated with higher-grade intracranial stenosis. This approach is favored for non-cardioembolic stroke as a cardiogenic mechanism tends to be best managed with attention to the cardiac condition as well as anticoagulant therapy. Risk stratification for recurrent stroke is important in weighing potential risk versus benefits. For example, prolonged dual antiplatelet therapy, with a combination such as aspirin and clopidogrel or aspirin and ticagrelor, tends to have negation of the potential clinical benefit of stroke prevention, over time, by the enhanced bleeding risk. Anticoagulant choices are now impacted by newer agents, initially identified as novel oral anticoagulants (NOACs), which also became associated with non-vitamin K agents as they are no longer considered novel. Alternatively, they are now often identified as direct oral anticoagulants (DOACs). They tend to be viewed as superior or non-inferior to warfarin with the caveat that warfarin is still viewed as the agent of choice for stroke prevention in patients with mechanical heart valves.Based upon cumulative information from multiple clinical trials of secondary prevention of stroke, there is an increasing array of approaches in an effort to provide optimal management. Antithrombotic therapy, including in combination with anticoagulant therapy, continues to evolve with the general caveat that one size does not fit all. In view of this, we desire to provide an evidence-based approach for the prevention of stroke with antithrombotic agents." @default.
• W4200468462 created "2021-12-31" @default.
• W4200468462 creator A5040456439 @default.
• W4200468462 creator A5079558294 @default.
• W4200468462 date "2021-12-14" @default.
• W4200468462 modified "2023-10-14" @default.
• W4200468462 title "Antithrombotic Therapy in the Prevention of Stroke" @default.
• W4200468462 cites W10734288 @default.
• W4200468462 cites W1608454038 @default.
• W4200468462 cites W191849520 @default.
• W4200468462 cites W1965320794 @default.
• W4200468462 cites W1969928268 @default.
• W4200468462 cites W1971442835 @default.
• W4200468462 cites W1991655882 @default.
• W4200468462 cites W1998972546 @default.
• W4200468462 cites W2016875529 @default.
• W4200468462 cites W2027538725 @default.
• W4200468462 cites W2030977683 @default.
• W4200468462 cites W2048615527 @default.
• W4200468462 cites W2060607835 @default.
• W4200468462 cites W2096246254 @default.
• W4200468462 cites W2097657831 @default.
• W4200468462 cites W2097854437 @default.
• W4200468462 cites W2100209149 @default.
• W4200468462 cites W2101486946 @default.
• W4200468462 cites W2107933782 @default.
• W4200468462 cites W2113089341 @default.
• W4200468462 cites W2118857793 @default.
• W4200468462 cites W2120544643 @default.
• W4200468462 cites W2121298865 @default.
• W4200468462 cites W2123634131 @default.
• W4200468462 cites W2124247204 @default.
• W4200468462 cites W2127743767 @default.
• W4200468462 cites W2136489990 @default.
• W4200468462 cites W2149388786 @default.
• W4200468462 cites W2150144608 @default.
• W4200468462 cites W2154940301 @default.
• W4200468462 cites W2159193915 @default.
• W4200468462 cites W2313667716 @default.
• W4200468462 cites W2361921955 @default.
• W4200468462 cites W2399388987 @default.
• W4200468462 cites W2435343268 @default.
• W4200468462 cites W2460117772 @default.
• W4200468462 cites W2465663631 @default.
• W4200468462 cites W2477288824 @default.
• W4200468462 cites W2499224120 @default.
• W4200468462 cites W2528028260 @default.
• W4200468462 cites W2749380187 @default.
• W4200468462 cites W2779726076 @default.
• W4200468462 cites W2800285152 @default.
• W4200468462 cites W2803966697 @default.
• W4200468462 cites W2804570339 @default.
• W4200468462 cites W2891654188 @default.
• W4200468462 cites W2904821510 @default.
• W4200468462 cites W2914750394 @default.
• W4200468462 cites W2924498637 @default.
• W4200468462 cites W2943431166 @default.
• W4200468462 cites W2945128656 @default.
• W4200468462 cites W2945825099 @default.
• W4200468462 cites W2969448124 @default.
• W4200468462 cites W3011312705 @default.
• W4200468462 cites W3012423066 @default.
• W4200468462 cites W3013474864 @default.
• W4200468462 cites W3014034754 @default.
• W4200468462 cites W3015209971 @default.
• W4200468462 cites W3043492355 @default.
• W4200468462 cites W3098781229 @default.
• W4200468462 cites W311320695 @default.
• W4200468462 cites W3127415852 @default.
• W4200468462 cites W3162833931 @default.
• W4200468462 cites W4229847571 @default.
• W4200468462 cites W4239612804 @default.
• W4200468462 cites W4248537673 @default.
• W4200468462 cites W4362054082 @default.
• W4200468462 doi "https://doi.org/10.3390/biomedicines9121906" @default.
• W4200468462 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34944719" @default.
• W4200468462 hasPublicationYear "2021" @default.
• W4200468462 type Work @default.
• W4200468462 citedByCount "4" @default.
• W4200468462 countsByYear W42004684622022 @default.
• W4200468462 countsByYear W42004684622023 @default.
• W4200468462 crossrefType "journal-article" @default.
• W4200468462 hasAuthorship W4200468462A5040456439 @default.
• W4200468462 hasAuthorship W4200468462A5079558294 @default.
• W4200468462 hasBestOaLocation W42004684621 @default.
• W4200468462 hasConcept C126322002 @default.
• W4200468462 hasConcept C127413603 @default.
• W4200468462 hasConcept C164705383 @default.
• W4200468462 hasConcept C177713679 @default.
• W4200468462 hasConcept C2776301958 @default.
• W4200468462 hasConcept C2777015399 @default.
• W4200468462 hasConcept C2777628954 @default.
• W4200468462 hasConcept C2777849778 @default.
• W4200468462 hasConcept C2778205648 @default.
• W4200468462 hasConcept C2779161974 @default.
• W4200468462 hasConcept C2780645631 @default.
• W4200468462 hasConcept C2780868729 @default.
• W4200468462 hasConcept C2780890252 @default.

• next